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Abstract
Background: Bioenergetic characterisation of malignant tissues revealed that different tumour cells can catabolise
multiple substrates as salvage pathways, in response to metabolic stress. Altered metabolism in gliomas has received a
lot of attention, especially in relation to IDH mutations, and the associated oncometabolite D-2-hydroxyglutarate (2-HG)
that impact on metabolism, epigenetics and redox status. Astrocytomas and oligodendrogliomas, collectively called
diffuse gliomas, are derived from astrocytes and oligodendrocytes that are in metabolic symbiosis with neurons;
astrocytes can catabolise neuron-derived glutamate and gamma-aminobutyric acid (GABA) for supporting and
regulating neuronal functions.
Methods: Metabolic characteristics of human glioma cell models – including mitochondrial function, glycolytic
pathway and energy substrate oxidation – in relation to IDH mutation status and after 2-HG incubation were studied
to understand the Janus-faced role of IDH1 mutations in the progression of gliomas/astrocytomas. The metabolic and
bioenergetic features were identified in glioma cells using wild-type and genetically engineered IDH1-mutant
glioblastoma cell lines by metabolic analyses with Seahorse, protein expression studies and liquid chromatography-
mass spectrometry.
Results: U251 glioma cells were characterised by high levels of glutamine, glutamate and GABA oxidation. Succinic
semialdehyde dehydrogenase (SSADH) expression was correlated to GABA oxidation. GABA addition to glioma cells
increased proliferation rates. Expression of mutated IDH1 and treatment with 2-HG reduced glutamine and GABA
oxidation, diminished the pro-proliferative effect of GABA in SSADH expressing cells. SSADH protein overexpression
was found in almost all studied human cases with no significant association between SSADH expression and
clinicopathological parameters (e.g. IDH mutation).
Conclusions: Our findings demonstrate that SSADH expression may participate in the oxidation and/or consumption
of GABA in gliomas, furthermore, GABA oxidation capacity may contribute to proliferation and worse prognosis of
gliomas. Moreover, IDH mutation and 2-HG production inhibit GABA oxidation in glioma cells. Based on these data,
GABA oxidation and SSADH activity could be additional therapeutic targets in gliomas/glioblastomas.
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Introduction
Gliomas, glial cell derived central nervous system malig-
nancies, are a heterogeneous, aggressive tumour type with
poor prognosis. The incidence of isocitrate dehydrogenase
(IDH) mutations is high in low-grade gliomas. Despite the
fact that these malignancies are still incurable, patients
with IDH-mutant gliomas have a better prognosis and re-
sponse to chemo-and radiotherapy than patients with
IDH wild-type tumours [1, 2]. IDH mutations can also be
implicated in the formation of other tumour types (acute
myeloid leukaemia – AML, chondrosarcomas, intrahepa-
tic cholangiocarcinoma – ICC). In these non-glial malig-
nancies, IDH mutations appear to confer a worse
prognosis to the patient; although there is some contro-
versy in case of ICC and AMLs [3, 4].
Based on highly detailed analyses of the genetic basis for
malignant progression (gene amplifications, mutations,
loss of chromosome arms, gene expression, DNA methy-
lation status), several altered pathways in IDH-mutated
gliomas were characterised, including RTK-PI3K-mTOR,
Notch signalling, cell cycle and DNA damage response
regulation. These studies concluded that IDH mutation is
at the centre of epigenetic alterations in glioma cells [5, 6].
The prevalence of IDH mutation is high in grade II-III
and secondary glioblastomas (70–80%), the most fre-
quently (> 90%) mutated IDH isoform is the cytosolic
IDH1 R132H [7, 8], that has gained a neomorphic activity
resulting in conversion of α-ketoglutarate (aKG) to the
oncometabolite D-2-hydroxyglutarate (2-HG). In addition,
the mutation has a negative impact on the function on the
wild-type allele [9].
2-HG can accumulate to millimolar concentrations in
cells and in the extracellular environment [10, 11]. More-
over, mutated IDH1 not only causes 2-HG production,
but also initiates changes in metabolic adaptation of mu-
tated cells [12]. Mutant IDH1 oxidises NADPH to NADP+
during 2-HG production, instead of reducing NADP+ to
NADPH as is done by the wild-type IDH1 enzyme during
conversion of isocitrate to aKG. Because 2-HG and aKG
are structurally very similar metabolites, 2-HG acts as a
competitive inhibitor of aKG-dependent dioxygenases in-
cluding prolyl-hydroxylases, histone- and DNA demethy-
lases [13–15]. Cancer-related metabolic alterations,
adaptations and their role in tumourigenesis and progres-
sion are extensively studied in many cancers. The meta-
bolic characterisation of human gliomas started with the
reinterpretation of Warburg effect suggesting that other
substrates than glucose can also be oxidised by glioma
cells [12, 16, 17], such as glutamine and acetate [18–20].
Multiple substrates can fill up the TCA cycle – which is
in the centre of metabolic activity – to provide acetyl-CoA;
and many studies reported that cells can use glutamine
and/or glutamate as catabolic substrates [21–23]. Previous
results suggested that glioma cells adaptively run the TCA
cycle backwards to power the electron transport chain, es-
pecially in case of IDH-mutant cells. Analogous to fumar-
ate hydratase (FH) and succinate dehydrogenase (SDH)
mutations, which can also cause oncometabolite produc-
tion, IDH mutation provides an example of how a single
mutation can reprogram cellular metabolism and affect
pathobiology [13, 15, 24].
Recent years have yielded exciting findings in the field
of tumour metabolism, and some aspects of these meta-
bolic alterations related to IDH mutations have also been
described [25, 26].
Astrocytes and GABA-ergic and glutamatergic neurons
play roles in the maintenance of the neurotransmitter
pools of glutamate and gamma-aminobutyric acid (GABA).
Astrocytes and neurons are in metabolic symbiosis, astro-
cytes can catabolise glutamate and GABA for supporting
and regulating neuronal functions. GABA can feed the
TCA cycle via the activities of GABA transaminase and
succinic semialdehyde dehydrogenase (SSADH) to produce
succinate [27]. The expression changes of GABA utilisation
enzymes and GABA consumption were only studied in few
recent publications in cancer research [28, 29].
An emerging question is whether glioma cells have the
ability to use the GABA shunt to support energy pro-
duction and proliferation. This indicates a need to
understand the effect of produced 2-HG (caused by
IDH1 mutations) on the former pathway.
Our study provides an exciting opportunity to advance
our knowledge of the effects of IDH1 mutation and
2-HG accumulation to identify several mechanisms
which can help to understand the Janus-faced role of
IDH1 mutations in the progression of gliomas – IDH
mutations could be driver oncogenic alterations, how-
ever, IDH-mutant human gliomas have better prognosis
than wild-type. In the present study, the alterations of
bioenergetic characteristics and different substrate oxi-
dation capacities in relation to the expressions of rele-
vant proteins in glioma cell lines were analysed
(Additional file 1: Figure S1 summarises the analysed
pathways). Our presented results demonstrate that
SSADH expression – an IDH mutation independent in
vivo characteristic of human glioma cells – provides a
possibility for GABA oxidation. This may have special
importance in survival, proliferation and metabolic adap-
tation of glioma cells.
Methods
All materials were purchased from Merck-Sigma-Aldrich
(Darmstadt, Germany), except where it is indicated in
the text.
In vitro cell cultures
U251 MG (U251 wt), genetically engineered U251 MG
mutant IDH1 R132H overexpressing (U251 IDH1m)
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[25], U87 MG (ATCC) and U373 MG (kindly provided
by G. Sáfrány) human astrocytoma/glioblastoma cells
were cultured in DMEM high glucose medium supple-
mented with 10% foetal bovine serum, 2 mM L-glutamine
and 100 UI/ml penicillin-streptomycin. R132H mutation
status was confirmed by immunocytochemistry using
anti-IDH1 R132H (Dianova, H09 clone, 1:80) antibody in
different cell lines after paraformaldehyde (4%) fixation. For
metabolic flux experiments, cells were washed with DMEM
D5030 (glucose-, glutamine- and pyruvate-free medium)
followed by incubation with DMEM D5030 medium con-
taining U-13C-glucose, U-13C-glutamine or 2-13C-acetate
(Cambridge Isotope Laboratories Inc.). T25 or T75 flasks
(for Western blot, liquid chromatography-mass spectrom-
etry (LC-MS) and 13C-labelling experiments) and 96-well
plates (sulforhodamine-B and Alamar Blue proliferation as-
says), special Seahorse plates were used with appropriate
cell numbers (3–8 × 105 cells/flask or 2.5 × 103 – 5 × 104
cells/well) for different treatments and measurements. To
analyse the direct effect of 2-HG accumulation and the role
of GABA metabolism in U251 wt cells, 4 mM 2-HG, 5 mM
GABA and 0.6 mM vigabatrin were added for various time
periods (24 h, 72 h and 14/28 days). We selected concentra-
tions based on previous publications.
Cell proliferation measurements
Beside cell counting the proliferation rate was analysed
by sulforhodamine-B (SRB) assay which correlates to the
protein content of the analysed samples. For 72-h prolif-
eration assays 2.5 × 103 untreated or pre-treated glioma
cells/100 μl well were seeded; followed by incubation
under different conditions. Thereafter the cells were
fixed with 10% trichloroacetic acid subsequently stained
with SRB using 10 mM Tris, and the absorbance was
measured at 570 nm. In addition, Alamar Blue (Thermo
Fisher Scientific) test was also used for proliferation
studies. The incubation period was 4 h, fluorescence was
measured by Fluoroskan Ascent FL fluorimeter software
(Labsystems International). Percentages of proliferation
were given relative to control samples.
Expression analysis of different proteins by Western blot
Protein concentrations of cell extracts were measured
with using Bradford assay (Biorad). Equal amounts of pro-
teins were separated by 8–12% SDS-PAGE gels following
their transfer to PVDF membrane applying BioRad Trans
Blot Cell. Membranes were stained with Ponceau S, before
incubation the following primary antibodies were used in
expression studies: anti-phosphofructokinase P (PFKP)
(Cell Signaling 1:1000 #8164); anti-hexokinase 2 (HK2)
(Cell Signaling 1:1000 #2867); anti-β-F1-ATPase (ATPB)
(Abcam 1:2000 #14370), anti-glutaminase (Gls) (Abcam
1:1000 #156876); anti-acetyl-CoA synthetase 2 (ACSS2)
(Cell Signaling 1:1000 #3658); anti-alanine, serine, cysteine
-preferring transporter 2 (ASCT2) (Bethyl 1:2000
#A304-353A); anti-succinic semialdehyde dehydrogenase
(SSADH) (Abcam 1:1000 #129017); anti-GABA trans-
porter 1 (GAT1) (Abcam 1:500 #426). Finally, biotinylated
secondary antibodies, Vectastain Elite ABC Kit (Vector)
and enhanced chemiluminescence technique (Thermo
Fisher Scientific ECL Western Blotting Substrate) were
applied by using C-Digit System (Li Cor Biosciences) de-
tection equipment. The membranes were stripped and
probed by anti-β-actin antibody (Sigma-Aldrich; #A228;
1:5000), to prove equal protein loading as well.
Assay to detect cellular respiration and extracellular pH
changes
Real-time measurements of oxygen consumption rate
(OCR), reflecting mitochondrial oxidation and extracel-
lular acidification rate (ECAR), indicated as a parameter
of glycolytic activity, were performed on a Seahorse
XF96 Analyzer (Agilent Technologies, USA) based on
previous descriptions [30–32].
Glioma cell lines were plated in 100 μl complete DMEM
growth media at 1.5 × 104 cells/well density onto 96-well
Seahorse plates (Agilent Technologies, USA) 24 h prior to
the assays. The medium was removed and was replaced by
glucose-, glutamine- and pyruvate-free DMEM medium
(D5030 pH 7.4). The basal OCR and ECAR were calculated
via XF96 Analyzer software (Agilent Technologies, USA)
after 1.5-h incubation at this condition.
Following this, substrate utilisation was measured by
using different substrates in parallel wells.
During the measurements freshly prepared substrates
(glucose 10 mM, glutamine 2.5 mM, citrate 5 mM,
GABA 5 mM, lactate 5 mM, malate 10 mM, acetate
10 mM and glutamate 5 mM) and/or metabolic inhibi-
tors/modulators (oligomycin 2 μM, 2,4-dinitrophenol -
DNP 100 μM and antimycin A + rotenone 1–1 μM) were
injected into each well to reach the desired final working
concentration.
LC-MS/MS method for quantitative metabolite analysis
Intra- or extracellular metabolites - citrate, aKG, succin-
ate, fumarate, malate, glutamate, 2-HG - were extracted
by a modified method based on Szoboszlai et al. [33, 34].
Cells (minimum 5 × 105 cells) were quenched in liquid ni-
trogen. Metabolites were extracted from cells and in paral-
lel 300–500 μl supernatant by methanol-chloroform-H2O
(9:1:1) and vortexed at 4 °C. After centrifugation
(15,000×g, 10 min, 4 °C) the clear supernatants were
stored at -80 °C until measurements. Citrate, aKG, succin-
ate, fumarate, malate, glutamate and 2-HG concentrations
were assessed by using calibration curves obtained with
the dilution of analytical purity standards in the range of
0.5–50 μM. LC-MS grade water, LC-MS grade methanol
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and LC-MS grade formic acid were purchased from VWR
International Ltd. (Debrecen, Hungary).
LC-MS/MS assays were performed on a Perkin-Elmer
Flexar FX10 ultra-performance liquid chromatograph
coupled with a Sciex 5500 QTRAP mass spectrometer.
For chromatographic separation a Phenomenex Luna
Omega C18 column, (100 × 2.1 mm, 1.6 μm) was used
(GenLab Ltd., Budapest, Hungary). The mobile phase
consisted of water containing 0.1% (v/v) formic acid (A)
and methanol containing 0.1% (v/v) formic acid (B). The
mass spectrometer was operating in negative electro-
spray ionisation mode with the following settings: source
temperature: 300 °C ionisation voltage: − 4000 V, curtain
gas: 35 psi, gas1: 35 psi, gas2: 35 psi, entrance potential:
-10 V, CAD gas: medium. Quantitative analysis was per-
formed in multiple reaction monitoring (MRM) mode.
Different substrate consumptions were analysed using
13C-labelling and LC-MS measurements
Sub-confluent cells were washed and incubated in DMEM
D5030 medium with 10 mM D-U-13C-glucose or
4 mM L-U-13C-glutamine or 10 mM 2-13C-acetate (Cam-
bridge Isotope Laboratories, Andover, MA, USA) addition
for 1 h in short-time labelling experiments before the ex-
traction [32]. In 24-h labelling experiments – avoiding
long-term starvation/non-physiological conditions – cells
were seeded in DMEM D5030 medium supplemented
with FBS, and the combination of labelled and/or un-
labelled glucose (10 mM) and glutamine (4 mM) or acet-
ate (10 mM) were added to cell cultures for 24 h.
SSADH expression analysis by immunohistochemistry
(tissue microarray) in clinical samples
47 glioma patients (type: astrocytoma n = 14, oligo-
dendroglioma n = 14, glioblastoma n = 19; sex: female n
= 23, male = 24; WHO grade: II n = 9, III n = 19, IV n =
19; IDH1 R132H mutation: positive n = 32, negative n =
15) were included in a tissue microarray (TMA) study.
Three normal brain and renal tissues were included as
controls. Expression studies by IHC on biopsy materials
were approved by the Institutional Ethical Review Board
(TUKEB no. 7/2006). TMA sections were deparaffinised,
endogenous peroxidase blocking was followed by antigen
retrieval (sodium citrate; pH 6). Immunostaining was
performed by routine diagnostic antibodies (such as
anti-IDH1 R132H), SSADH (Abcam #129017 1:500)
antibody and Novolink Polymer Detection System
(Novocastra, Wetzlar, Germany), visualised by DAB and
counterstained with haematoxylin. H-scores (scale of 0–
300) were determined by two independent pathologists
with semi quantitative analysis of immunoreactivity
using 3DHistech Pannoramic Viewer program according
to Krencz et al. [35]. The H-score was calculated from
staining intensity (0, 1+, 2+, or 3+) and positively stained
tumour cells (percentage). The final H-score was calcu-
lated by averaging the H-scores of all the scores from
the same tissue. SSADH expression was categorised as
low (H-score 0–149) and high (H-score 150–300).
Statistical analysis
The data are presented as mean with standard deviation
and calculated from three independent experiments with
minimum three or more parallels depending on the
method used. Results were statistically evaluated through
one-way ANOVA with post-hoc Tukey’s and Dunnett’s
tests for multiple comparisons by IBM SPSS Statistics soft-
ware, version 22 (SPSS Inc.). Mann-Whitney U test and
Kruskal-Wallis test were used to compare SSADH expres-
sions and clinicopathologic parameters in human gliomas
using IBM SPSS Statistics software, version 22 (SPSS Inc.).
p < 0.05 was considered statistically significant.
Results
Characteristics of cellular respiration and glycolytic
activity in glioma cells
The basal oxygen consumption rates (OCR) among the in-
vestigated gliomas showed significant differences. The
lowest respiration rate was observed in U87 MG, while
the highest basal rate was produced by U373 MG cells in
DMEM D5030 medium (Fig. 1a). In contrast with the re-
spiratory parameters, there were no differences in the
basal extracellular acidification (ECAR) rates. However,
glucose addition reveals alteration in the metabolic adap-
tation of gliomas. Lactate productions using glucose ad-
ministration with or without mitochondrial respiratory
inhibitor were the highest in U87 MG cells, which have
the lowest basal respiratory activity (Fig. 1b). These find-
ings indicate an inverse relationship between the basal
oxygen consumption and the glycolytic activity. Addition-
ally, we compared the glutamine metabolising properties
of the examined gliomas. The glutaminolysis-driven re-
spiratory capacity was significantly higher in U251 wt cells
than in U87 MG or U373 MG cells (Fig. 1c). Using same
cell density, time-dependent growth showed individual
differences in these glioma cells (Fig. 1d), but these did
not correlate to their oxygen consumptions. U373 MG
cells have the fastest proliferation and these cells have
both high glucose utilisation and high respiratory capacity.
IDH1 mutation and related 2-HG accumulation increase
the basal respiration and decrease the glycolytic capacity
The effects of the most frequent IDH1 mutation (R132H)
of gliomas in energy metabolism and substrate consump-
tion were studied in an IDH1 mutation (R132H) carrying
glioma model (isogenic pair: U251 wt and its genetically
engineered counterpart - U251 IDH1m). Besides, we stud-
ied the short-term effects of 2-HG incubation in U251 wt
cells. Comparing the basal respiration of wt, 2-HG-treated
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wt and IDH1m U251 cells, significantly elevated OCR was
observed in case of IDH1m and 2-HG-treated wt cells
(Fig. 2a). In contrast, higher extracellular acidification
rates – especially after glucose addition – were measured
in U251 wt cells compared to IDH1m and 2-HG-treated
U251 wt cells (Fig. 2b). These alterations were detected by
Seahorse measurements, the altered characteristics related
to IDH1 mutation and 2-HG treatment were supported
by Western blot analyses of certain metabolic enzyme ex-
pressions in these models (Fig. 2c). Higher β-F1-ATPase
expression was detected in IDH1m cells in parallel with
increased OCR compared to wt cells. However, short-term
2-HG addition did not elevate the expression level of
β-F1-ATPase in U251 wt cells. Analysing certain key en-
zymes of glycolysis (e.g. hexokinase 2, phosphofructoki-
nase P), decrease in their expression was detected in
IDH1m and 2-HG-treated wt cells.
U251 wt and IDH1m cells have significantly different in
vitro growth characteristics. The proliferation of mutant
cells was lower than of wild-type cells registered by cell
number during culturing and SRB assay (doubling times
were calculated based on Roth V. et al. – [36] – the doub-
ling time of IDH1m cells was 1 h longer than wt by both
cell counting and proliferation assay. However, 72-h
(short-term) 2-HG treatment had no significant growing ef-
fect on cell proliferation rates in U251 wt cultures (Fig. 2d).
Intracellular metabolite concentration differences and the
main source of 2-HG production
The intracellular metabolite concentrations (measured by
LC-MS) confirmed the metabolic differences detected
among U251 cell culture systems (Fig. 3a). High level of
2-HG was measured in IDH1m cells and similar 2-HG
level was observed in 2-HG-treated wt cells by LC-MS
(Fig. 3b). Moreover, elevated levels of TCA metabolites
were observed in IDH1m and 2-HG-treated U251 wt cells
(Fig 3a). Inverse alterations were detected in glutamate
concentrations. The amount of glutamate was decreased
in IDH1m, but it was increased in 2-HG-treated wt cells
comparing to wt cells (Fig. 3b).
To identify which substrates are the prominent sources
for 2-HG production in IDH1-mutant U251 cells, the cells
were fed with 13C-labelled energy substrates (U-13C-glu-
cose, U-13C-glutamine, 2-13C-acetate) in D5030 medium.
Based on our 1-h-labelling results, both glutamine and
glucose could be sources of 2-HG (5.5% 13C-labelled
2-HG from glutamine and ~ 2% from glucose were de-
tected). Performing 24-h-labelling experiments, glutamine
was proven to be the main source of 2-HG – 87.43%
(sum-total =M+ n isotopomers) of the total intracellular
2-HG pool containing glutamine-derived 13C-labelling
(Fig. 3c), as compared to 13C-incorporation percentages of
15.95 and 15.7% from glucose and acetate, respectively
a
c
b
d
Fig. 1 Oxygen consumption, extracellular acidification rate and glutamine oxidation differences were measured by Seahorse in U87 MG, U251 wt,
U373 MG glioma cell lines using D5030 medium. a Different oxygen consumption rates in the studied cell lines (pmol/min). b Extracellular
acidification rates were measured in minimal medium (D5030) at basal rate and after glucose (10 mM) addition following oligomycin (2 μM)
treatment. c Oxygen consumption rate curves in minimal medium (D5030), and after glutamine (2.5 mM) addition and using several metabolic
inhibitors and modulators (oligomycin - 2 μM; 2,4-dinitrophenol - DNP - 100 μM; antimycin - 1 μM - and rotenone - 1 μM) *:p < 0.05. d Time-
dependent growth of different glioma cell lines (U87 MG, U251 wt and U373 MG) at normal non-starving conditions. Cell proliferation was
monitored by SRB test using 2.5 × 103 cells/100 μl at the starting point of the experiments
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(Fig. 3c). Labelling intensities of extracellular 2-HG levels
correlated to and followed the intracellular ones in our
measurements (Additional file 2: Figure S2).
IDH1 mutation and 2-HG related different substrate -
including GABA - oxidation in U251 MG models
Beside glucose and glutamine, other substrates were also
involved to study different substrate oxidations by Sea-
horse technique using wt, IDH1m and 2-HG-treated
U251 wt cells. No differences between U251 wt and
U251 IDH1m cells were detected with respect to lactate,
citrate or acetate oxidations. In contrast, decreased oxi-
dation of glutamine, glutamate and malate was measured
in IDH1m cells (Fig. 4a). 2-HG-treated U251 wt cells
mimicked IDH1m cells regarding oxidation (Fig. 4b). En-
zyme expressions related to glutamine and acetate con-
sumption were detected by Western blot (Fig. 4c).
Intriguingly, significant GABA oxidation was detected in
U251 wt cells (OCR was elevated with 20%) (Fig. 4a). How-
ever, IDH1m cells did not oxidise GABA and this could be
mimicked in 2-HG treated U251 wt cells (Fig. 4b). The
pro- or anti-proliferative effects of short- and long-term
GABA, 2-HG and GABA+ 2-HG combination treatments
were also tested in U251 wt and IDH1m cells. Long-term
GABA treatment (for more than 3 weeks) significantly en-
hanced the proliferation of U251 wt cells, whereas signifi-
cantly lower increase in proliferation was found in IDH1m
cells (Fig. 4d). While 2-HG could not significantly reduce
the proliferation of the long-term GABA treated IDH1m
cells, 2-HG combination treatments reversed long-term
GABA effects in the wild-type cells (Fig. 4d). Short-term
(72 h) GABA, 2-HG treatments and their combination
showed similar tendency in wild-type cells, however, no
significant effect could be observed (data not shown).
According to the Human Protein Atlas (http://
www.proteinatlas.org) database, U251 cells do not ex-
press GABA receptor subunit mRNAs (GABRA 1–6,
GABRB1–3, GABRR1–3, GABRE and GABRQ), exclud-
ing receptor mediated effects of GABA. However, U251
cells do express SSADH and GAT1 proteins as shown by
Western blot. Of note, SSADH and GAT1 protein level
differences in IDH1m and 2-HG-treated U251 wt cells
were also found (Fig. 4c.). Noteworthy, U87 MG and
U373 MG did not express SSADH. Accordingly, these cells
did not oxidise GABA (Fig. 5a and b). To test the potential
role of GABA shunt and SSADH activity in the survival
and the proliferation of SSADH expressing U251 wt cells,
we tested the effect of vigabatrin (GABA transaminase
a
c
b
d
Fig. 2 IDH1 mutation (IDH1m) and the elevated 2-HG level related metabolic alterations in U251 glioma cells (oxygen consumption and
metabolic enzyme expression differences). a Oxygen consumption rates in U251 wt, U251 IDH1m and 2-HG pre-treated (72 h, 4 mM) U251 wt
cells (OCR was measured in D5030 medium by Seahorse). b Extracellular acidification data in minimal medium (D5030), and after glucose
(10 mM) addition and using oligomycin (2 μM) thereafter (Seahorse measurements). c Alterations in the expression of different metabolic
enzymes in IDH1m and 2-HG-treated (72 h, 4 mM) U251 glioma cells (representative Western blot results using anti-β-F1-ATPase - ATPB, anti-
hexokinase 2 - HK2, anti-phosphofructokinase P - PFKP and β-actin). d Differences in proliferation of U251 wt, IDH1m and 2-HG pre-treated (72 h)
wt cells. The relative proliferation was calculated related to U251 wt (100%), the growing capacity was monitored by SRB tests using 2.5 × 103
cells/100 μl at the starting point of the experiments; *:p < 0.05
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inhibitor). Vigabatrin reduced the proliferation of glioma
cells, as we could see this slight decrease in U251 wt cell
cultures, as well. In U251 wt cells, vigabatrin could lower
GABA oxidation, and in case of the presence of vigabatrin,
GABA addition was not able to influence the cellular prolif-
eration positively (Additional file 3: Figure S3). The exact
role of SSADH in the detected GABA-dependent
pro-proliferative effect needs examinations using specific
SSADH inhibition in further studies.
SSADH overexpression in human glioma cases
In vitro cell lines do not necessarily reflect clinical tu-
mours in all aspects [37]. Therefore, SSADH expression
was studied in human glioma biopsies and peritumoural
normal brain tissues (both cerebrum and cerebellum) by
immunohistochemistry. In peritumoural cerebral tissues,
high expression with H-score > 150 was observed in the
cortical region, however, white matter astrocytes showed
low to moderate expression (150 > H-score). In the cere-
bellum, moderate to high expression was observed in
both the molecular and the granular cell layers similarly
to the Purkinje cells; we recorded that cells have low
SSADH staining intensity (0/+) at non-tumoural areas.
We could detect a moderate expression level in astro-
cytes of white matter in situ and 3+ positivity in glioma
cells. Based on our results, SSADH protein level is
higher in glioma cells than in normal tissues in almost
all studied cases; therefore, we could not find any differ-
ences between IDH-mutant and wild-type cases at this
level. In the glioma biopsies, high SSADH expression
was characteristic for all histological subtypes (Fig. 5c).
High SSADH expression was found in 97% of cases. This
SSADH expression showed no associations with clinico-
pathological parameters such as age, gender, tumour
type, grade or IDH mutation status.
Discussion
Our main aim was to characterise the bioenergetic differ-
ences related to IDH mutations by using an isogenic cell
line pair with and without the IDH1 R132H mutation.
The effects of epigenetic and other (e.g. metabolic) alter-
ations caused by IDH1 mutation have been described
a
c
b
Fig. 3 Altered metabolite concentrations in IDH1-mutant and 2-HG-treated (72 h, 4 mM) U251 wt cells and the evaluation of the bioenergetic
source of 2-HG production in U251 IDH1m cells (LC-MS measurements). a TCA cycle related metabolite levels (relative to wt) in IDH1m and 2-HG-
treated U251 wt cells - (DMEM high glucose medium + 10% FBS + 2 mM L- glutamine). b Alterations in intracellular glutamate and 2-HG levels
(relative to IDH1m) in 2-HG-treated U251 wt cells and in wt cells; u.d. = under detectable level - (DMEM high glucose medium 10% FBS + 2 mM L-
glutamine). c Unlabelled and 13C-labelled intracellular 2-HG productions (% of total 2-HG pool) (24-h labelling period). To avoid starving condition,
the medium was supplemented with 10% FBS and 10 mM D-glucose and/or 4 mM L-glutamine: 4 mM U-13C-glutamine labelling in D5030 + 10%
FBS and 10 mM D-glucose; 10 mM U-13C-glucose labelling in D5030 + 10% FBS and 4 mM L-glutamine; or 10 mM 2-13C-acetate labelling in D5030
medium + 10% FBS + 10 mM D-glucose and 4 mM L-glutamine. Unlabelled 2-HG does not contain incorporated 13C atoms, M + 1/2/3/4/5 =mass
number increased with 1/2/3/4 or 5 13C atoms in 2-HG from different labellings; *:p < 0.05
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previously [38–40]. However, few data are available about
the bioenergetic consequences of IDH1 mutation and
their role in growth and survival of tumour cells [25, 41].
Based on our Seahorse measurements (oxygen consump-
tion and extracellular acidification), higher oxygen con-
sumption is strongly correlated to mutant IDH1-produced
2-HG. In addition, after using 2-HG treatment in wild-type
cell cultures, the respiration was increased to similar level
as in IDH1-mutant cells. Alterations of intra- and extracel-
lular 2-HG besides Krebs cycle metabolite levels were ob-
served. These observations suggest the presence of
metabolic compensatory mechanisms in these cells. Our
results confirmed, that the Warburg phenotype is domin-
ant in IDH1 wild-type cells, whereas IDH1-mutant cells
prefer oxidative phosphorylation using substrates other
than glucose. Khurshed et al. published that glycolytic
enzyme mRNA expression levels are higher in IDH
wild-type tumour tissues and the expression levels of TCA
related enzymes are higher in IDH1-mutant human cases
[20]. It was also described that mutant IDH1 enzyme was
correlated with high mitochondrial density and increased
mitochondrial activity in oligodendroglioma cell line xeno-
grafts in vivo [41].
In our study, the significantly reduced glutamate level in
IDH1-mutant cells could correlate to enhanced glutamino-
lytic pathway (glutamine-glutamate-aKG-2-HG axis). This
was not observed in U251 wt cells after 2-HG incubation,
suggesting that glutamatolysis in IDH1-mutant cells is re-
lated to the necessity to replenish aKG levels, rather than by
2-HG induced effects [16]. Previous spectrometric analyses
have shown and highlighted that the most important source
of 2-HG is glutamine, and only low labelling could derive
from glucose due to limited glucose turnover [26]. Glutam-
ine was the main source of 2-HG in our experiments using
13C-labelled substrates in 1-h-and 24-h-labelling periods
which is in line with previous report [23]. Glucose and acet-
ate also contributed to 2-HG-labelling in 24-h 13C-labelling
experiments. This potential contribution of acetate substrate
in significant 2-HG 13C-labelling after 24 h was detected
first in our experiments. Previous TCGA-based analyses
a
c
b
d
Fig. 4 Energy substrate oxidation differences in wt, IDH1m and 2-HG-treated U251 wt cells. a Oxygen consumption compared to basal
respiration (%) after using different energy substrates: glucose (10 mM), glutamine (2.5 mM), citrate (5 mM), GABA (5 mM), acetate (10 mM),
malate (10 mM), lactate (5 mM), glutamate (5 mM) in U251 wt and U251 IDH1m cell lines in D5030 medium by Seahorse measurements, *:p <
0.05 **:p < 0.01. b Effects of 2-HG on glutamine and GABA oxidation in U251 wt, IDH1m and 2-HG-treated wt cells (the oxidation was measured
after with or without 2-HG (4 mM) pre-treatment (72 h) in D5030 by Seahorse measurements) *:p < 0.05, **:p < 0.01. c GABA metabolism related
enzyme (GAT1 - GABA transporter 1; SSADH - succinic semialdehyde dehydrogenase) expressions; glutamine metabolism related enzyme expressions
(glutaminase, ASCT2 - alanine, serine, cysteine-preferring transporter 2); and acetate consumption related ACSS2 (acetyl-CoA synthetase 2) enzyme
expression in U251 wt, IDH1m and 2-HG (4 mM) treated cells (72 h) using Western blot analyses. d Different growing characteristics of U251 wt and
U251 IDH1m cells using long-term (3-week-long) 2-HG (4 mM), GABA (5 mM) and combination treatments in DMEM high glucose. After 3-week long-
term continuous treatment (intermittently passaging 2 or 3 times per week) 2.5 × 103 cells/100 μl were plated for 72 h and terminated by SRB tests.
Data show the average of relative proliferations (untreated U251 wt – 100%) *: p < 0.05
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suggest that glucose and acetate are preferential substrates
in IDH wild-type, rather than IDH-mutant gliomas [20];
therefore, the relative contribution of glucose and acetate in
clinical IDH-mutant gliomas needs further investigations.
It has been shown in in silico studies that IDH1-mu-
tant gliomas have significantly higher lactate dehydro-
genase B expression comparing to wild-type tumours;
and higher lactate oxidation was hypothesised in IDH1
mutation bearing cells [20]. In our observations, we
could not detect significant differences in lactate and
acetate oxidation between wild-type and IDH1-mutant
glioma cells. However, our results show that glutamine,
glutamate and GABA energy substrates could significantly
increase oxygen consumption rate in IDH1 wild-type
U251 glioma cells (approximately 20% increase in OCR),
but not in their IDH1-mutant counterpart cells. These
suggest that GABA and glutamine can have an important
role in energy production through substrate oxidation
preferentially in IDH1 wild-type gliomas.
Dependency on glutamine and/or glutamate of IDH-
mutant gliomas has been reported previously [21, 23].
Our current study has demonstrated for the first time,
that GABA oxidation (using GABA as an energy sub-
strate) via the activity of SSADH can produce energy,
explaining our finding the GABA stimulated prolifera-
tion of U251 wild-type cells. However, emerging data
about the exact mechanism of GABA receptor mediated
pro-proliferative effects are still unclear and contradict-
ory [42, 43]. The detected pro-proliferative effect was
not the result of GABA-receptor stimulation [44] as
U251 cells lack expression of these. Based on our results,
2-HG could reverse the effect of GABA on proliferation.
In line with the absence of SSADH expression in U87
MG and U373 MG, these cell lines were not able to oxi-
dise GABA. Recent publications highlight the import-
ance of GABA shunt in primer and metastatic brain
tumours. The heterogeneity in cell lines with respect to
SSADH expression and GABA oxidation warrants fur-
ther investigation towards GABA use in human glioma
cases and in other tumours which may rely on the effect
of GABA use [28, 29, 45, 46]. Our IHC studies reveal
that both IDH-mutant and wild-type gliomas express
high levels of SSADH in contrast to normal brain, sug-
gesting certain role for GABA in growth and survival in
clinical tumours. This correlates to data of Human Pro-
tein Atlas, where 90% of studied human gliomas showed
moderate or high SSADH expression which indicates a
significantly higher expression than normal brain tissue.
Related to these El-Habr and his co-workers have demon-
strated that the accumulation of gamma-hydroxybutyrate
(by-product of GABA in central nervous system) and the re-
lated SSADH downregulation contribute to a less aggressive
a
b
c
Fig. 5 GABA oxidation and SSADH expression differences in glioma cell lines; and common SSADH expression in human glioblastoma/glioma
samples. a Oxygen consumption rates after using GABA - as an energy substrate - in U251 wt, U251 IDH1m, U87 MG and U373 MG cells in D5030
(representative oxygen consumption curves - Seahorse measurements). b SSADH expression in U251 wt, U251 IDH1m, U87 MG and U373 MG
cells (representative Western blot results). c Summarised data about the evaluation of SSADH expressions in wt and IDH1m human samples
(upper diagram) and in different human glioma types (lower diagram) and representative IHC stainings with HE counterstaining (DAB-brown
staining, magnification 200×; normal human brain tissue and kidney were used as controls). ODG-oligodendroglioma, AC-astrocytoma and
GBM-primer glioblastoma
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phenotype in glioblastoma cases. They found higher SSADH
protein expression in glioma cells than in normal brain tis-
sue. They also described that downregulation, lowered ex-
pression and inhibited function of SSADH (shRNA
silencing and gamma-hydroxybutyrate – structurally shows
similarities to aKG and 2-HG – treatment) correlated to
lower proliferation capacity of glioma cells in vitro and in
vivo [47]. Regarding to high-grade gliomas which showed
lower SSADH expression at mRNA level in TCGA database,
in our study (47 cases were analysed), we could not confirm
this difference at protein level. Based on our and others’ re-
sults, SSADH protein level is higher in almost all glioma
cells than in normal tissues. These suggest that SSADH pro-
tein overexpression at tissue level could have special tumour
cell survival and growth promoting effect in both
IDH-mutant and wild-type cases. To clarify the role of
GABA metabolism, SSADH expression and functions need
further studies using both mRNA and protein expression
studies with patient follow-up. In these studies, overall sur-
vival data evaluations and if it is possible some SSADH func-
tion related analyses should be performed.
Our findings suggest that 2-HG may contribute to a less
aggressive phenotype through its inhibitory effect on
GABA oxidation. The detected SSADH overexpression in
human cases could support GABA metabolism through
either GABA oxidation or alternative GABA consump-
tions. Regarding to our and others’ results, GABA metab-
olism of gliomas might be a possible novel entry point for
therapy, especially in glioma patients with poor prognosis
and limited treating opportunities.
Conclusions
As discussed above, evaluating the dominant bioener-
getic pathways, preferred substrates (such as glutamine
or GABA) which can support tumour growth could help
to understand metabolic reprogramming and adaptation
facility better in glioma cells, and to seek new alterna-
tives for targeted therapy in this incurable aggressive dis-
ease, respectively.
Additional files
Additional file 1: Figure S1. Simplified scheme of the examined
bioenergetic pathways in the studied IDH1 wild-type and mutant glioma
cells. In our study, different energy substrate oxidation and metabolic
enzymes relating to the following bioenergetic pathways were analysed
regarding the role of IDH1 mutation. Energy substrate oxidation: glucose,
glutamine, citrate, GABA, acetate, malate, lactate and glutamine were
measured by Seahorse technique. Energy metabolites - succinate,
fumarate, malate, citrate, α-ketoglutarate, glutamate and 2-
hydroxyglutarate were determined by liquid chromatography-mass
spectrometry. Several protein expressions were measured by Western
blot analysis or immunohistochemistry - Glycolysis: hexokinase 2 (HK2),
phosphofructokinase P (PFKP), Glutaminolysis: alanine, serine, cysteine-
preferring transporter 2 (ASCT2), glutaminase (Gls), GABA shunt: GABA
transporter (GAT1), succinic semialdehyde dehydrogenase (SSADH),
acetate consumption: acetyl-CoA synthetase 2 (ACSS2). Other
abbreviations can be found in the figure: GLUT1: glucose transporter 1,
IDH: isocitrate dehydrogenase, LDH: lactate dehydrogenase, MCT1:
monocarboxylate transporter 1, OAC: oxaloacetate, SSA: succinic
semialdehyde. (PDF 348 kb)
Additional file 2: Figure S2. Extracellular 2-HG levels after 13C-substrate
labellings detected by LC-MS in U251 IDH1m cells. a., 2-HG pool after
24 h following 13C-substrates incubation: 4 mM U-13C-glutamine labelled
intra- and extracellular 2-HG. b., 10 mM U-13C-glucose labelled extracellular
2-HG in D5030. c., 10 mM 2-13C-acetate labelled 2-HG in D5030. Unlabelled
2-HG did not contain incorporated 13C atoms, M + 1/2/3/4/5 =mass number
increased with 1/2/3/4 or 5 13C atoms in 2-HG from different labellings (the
low rate of M + 4 is not visible in the figure). The labelling conditions were
given in the legends of Fig 3. (PDF 197 kb)
Additional file 3: Figure S3. Vigabatrin abolished the pro-proliferative
effect of GABA a., The effect of GABA (5 mM), vigabatrin (0.6 mM) and
GABA+vigabatrin on the proliferation of U251 wt glioma cells. SRB and
Alamar Blue (AB) proliferation assays were used in 24-h treated cell
cultures; b., Alterations in cell numbers (U251 wt cells) followed in
every 4-day passage using 3-week continuous treatment, the average
cell numbers were calculated from triplicates. (PDF 198 kb)
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